Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.

NAUnknownINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Ferrous fumarate

Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.

DRUG

MonoFer

Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.

Trial Locations (1)

2300 RC

RECRUITING

Leiden University Medical Centre, Leiden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

Rijnstate Hospital

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Sint Franciscus Gasthuis

OTHER

collaborator

Adrz, Goes

UNKNOWN

collaborator

Medical Center Haaglanden

OTHER

lead

Leiden University Medical Center

OTHER